Novavax, the Maryland vaccine developer, has turned itself into a company that earns most of its money from partners, led by Sanofi, which now sells its Covid vaccine. It ended September with $627m of cash and investments and $292.1m of long-term debt, and it has raised its 2026 revenue outlook after a $125m milestone. It is still losing money, and much of its future income depends on Sanofi.
What Novavax does
Novavax is based in Gaithersburg, Maryland, and its shares trade on Nasdaq as NVAX. It develops protein-based vaccines. Its two main assets are Nuvaxovid, its Covid vaccine, and Matrix-M, an adjuvant that boosts the immune response to vaccines and can be licensed to other companies.
In May 2024 Novavax signed an agreement with Sanofi. Sanofi now sells Nuvaxovid and pays Novavax royalties on its global sales, can develop combined flu and Covid vaccines that use it, and can create new vaccines with Matrix-M. Takeda sells the vaccine in Japan, and the Serum Institute of India co-formulates and fills it.
An updated version of Nuvaxovid, matched to the XFG Covid variant, was approved in the US, the EU and Japan in August, and Sanofi and Takeda began selling it for the 2026-2027 season. In its own pipeline, Novavax expects a vaccine candidate against C. difficile bacteria to enter clinical trials as early as 2027, after presenting early laboratory data in September. Several studies of Matrix-M, run by Novavax and by partners in infectious disease and cancer, are under way and could lead to further licensing deals.
Novavax: share price, chart and news

How the Sanofi deal pays
| Stream | What Novavax can earn | Status |
|---|---|---|
| Nuvaxovid milestones | Up to $350m | $75m still to come on completion of the technology transfer, expected mid-2027 |
| Nuvaxovid royalties | High-teens to low-twenties percent of Sanofi's net sales | Payable on Sanofi's sales, which began this season |
| Flu and Covid combination milestones | Up to $350m | $125m earned in October 2026; $225m on a US launch |
| Combination royalties | High-single-digit to sub-teens percent | Only after launch |
| New Matrix-M vaccines | Up to $200m in milestones each for the first four, plus mid-single-digit royalties | Depends on Sanofi's programmes |
The $125m payment was triggered when Sanofi dosed the fifth patient in a Phase 3 trial in Europe of Nuvaxovid given with its high-dose flu vaccine in adults aged 60 and over. Sanofi intends to start a US Phase 3 trial in 2027. Novavax says the partnership has brought in more than $1bn so far. Takeda pays annual milestones and mid-to-high-teens percentage royalties in Japan.
The latest numbers
| Measure | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Total revenue | $68.3m | $70.4m | $264.5m | $976.3m |
| Product sales | $25.7m | $13.4m | $86.7m | $645.8m |
| Research and development | $52.4m | $98.3m | $218.6m | $266.4m |
| Selling, general and administrative | $23.6m | $31.7m | $79.1m | $123.4m |
| Net income (loss) | -$31.4m | -$202.4m | -$94.3m | $422.8m |
Revenue has fallen sharply from last year's levels, while spending has been cut as Sanofi took over selling the vaccine and seasonal strain-change work shrank. Research reimbursements from Sanofi are nearing their end, which cut licensing income in the third quarter.
Partner income in the quarter came from Sanofi ($19m), Takeda ($7m), the Serum Institute ($5m) and other partners ($11m). The quarter also included $11m of non-cash deferred royalty income linked to earlier Nuvaxovid sales by SK bioscience. On an adjusted basis, which strips out some non-cash items, research spending was $48.7m, down 7% from a year earlier.
For 2026, Novavax now expects adjusted total revenue of $385m to $415m, up from $235m to $275m, with the $125m milestone included. It expects combined research and administrative costs of $375m to $395m.
Cash, debt and shares
At 30 September 2026
- $627m cash, cash equivalents, marketable securities and restricted cash
- $292.1m long-term debt, net of issuance costs
- 165.0m shares outstanding on 31 October
Cash fell from $751m at the end of 2025, and operations used $199.5m in the first nine months. The debt is made up of $26.5m of 5.00% convertible notes due 2027, $225.0m of 4.625% convertible notes due 2031 and $50.0m drawn under a loan from MidCap Financial of up to $330.0m. That loan is secured on substantially all of Novavax's assets, carries a floating rate that stood at 8.7% at the end of September, and requires the company to hold at least $100m of unrestricted cash at all times. Repaying it early costs a premium of 1% to 3%, plus a 2.75% exit fee.
Shareholders' equity was negative at $216.9m. Management expects to have enough capital for at least a year from the date of the accounts.
Risks and what to watch
Main risks
- Reliance on Sanofi. The largest future payments depend on Sanofi's trials, approvals and sales.
- Falling Covid demand. Nine-month revenue fell by almost three quarters from a year earlier.
- Refund and partner liabilities. Up to $92.5m of deferred revenue under an Australian supply deal could become refundable if an updated vaccine is not approved and delivered in time, and Novavax is awaiting a decision from the Australian regulator. It also carries $210m of liabilities to Gavi.
- Key supplier. It depends heavily on the Serum Institute of India to co-formulate, fill and finish its Covid vaccine.
- Debt. Secured debt carries a minimum-cash covenant, and convertible notes fall due in 2027 and 2031.
| When | What |
|---|---|
| Q4 2026 results | First results to include the $125m Sanofi milestone, earned in October |
| 2026-2027 season | Royalties from Sanofi and Takeda sales of the updated Nuvaxovid |
| Mid-2027 | Expected completion of the technology transfer to Sanofi and a $75m milestone |
| 2027 | Planned start of Sanofi's US Phase 3 combination vaccine trial |
| 2027 | C. difficile vaccine candidate could enter the clinic |
| Not dated | $225m milestone on a US launch of a combined flu and Covid vaccine |
Sources
- Novavax (Form 8-K, Exhibit 99.1): Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights (2026-11-05)
- Novavax (Form 8-K, Exhibit 99.1): Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe (2026-10-29)
- U.S. Securities and Exchange Commission (EDGAR): Novavax, Inc. Form 10-Q for the quarter ended 30 September 2026 (2026-11-05)
- U.S. Securities and Exchange Commission (EDGAR): Novavax, Inc. Form 10-Q cover page (shares outstanding) (2026-11-05)








